It is currently Sat Aug 19, 2017 10:01 pm



All times are UTC - 5 hours [ DST ]


Our Sponsors





Post new topic Reply to topic  [ 2 posts ] 
Author Message
 Post subject: Generic Suboxone film?
PostPosted: Wed Nov 30, 2011 9:25 am 
Offline
Long Time Member
Long Time Member
User avatar

Joined: Thu Jul 15, 2010 5:08 am
Posts: 1503
I had no idea about this, but it's very interesting.

This company BEMA has a "proprietary technology" that seems to be a lot like Suboxone film. They've been doing studies in comparing their buprenorphine / naloxone product with Suboxone, with apparent success.

Check it out:

Quote:
BEMA Buprenorphine/Naloxone

BioDelivery Sciences is developing BEMA Buprenorphine/Naloxone for the treatment of opioid dependence. The product will combine a "high dose" of buprenorphine along with an abuse deterrent agent, naloxone. Preliminary pharmacokinetic studies have demonstrated the ability of the BEMA technology to deliver the high doses of buprenorphine necessary for the treatment of opioid dependence.

A BEMA Buprenorphine/Naloxone product would provide BDSI with an opportunity to compete in a rapidly growing opioid dependence market. Buprenorphine is widely used in the treatment of opioid dependence and is marketed as Suboxone® (buprenorphine/naloxone) and Subutex® (buprenorphine). Accordingly to Wolters Kluwer, U.S. sales of buprenorphine containing products for the treatment of opioid dependence exceeded $1 billion in 2010. Initial pharmacokinetic studies have demonstrated the ability of the BEMA technology to deliver doses of buprenorphine needed for the treatment of opioid dependence.


http://www.bdsi.com/Other_BEMA_Products.aspx

Also:

Quote:
Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced positive preliminary results from its Phase 1 study assessing the pharmacokinetics of a BEMA Buprenorphine/Naloxone formulation. BDSI is seeking to develop and commercialize a high dose formulation of buprenorphine combined with naloxone (abuse deterrent agent) for the treatment of opioid dependence.

This study assessed buprenorphine and naloxone absorption profiles from BDSI's BioErodible MucoAdhesive (BEMA) formulation of buprenorphine/naloxone versus the FDA approved and currently marketed opioid dependence product, Suboxone. Results of the study demonstrated the ability of the BEMA formulation to meet the key pharmacokinetic goal of delivering plasma concentrations of buprenorphine in the range needed to treat opioid dependence while minimizing the exposure of naloxone.

"We are pleased with the results of this study as they are consistent with our expectations and allow us to now optimize our BEMA Buprenorphine/Naloxone formulation prior to conducting the pivotal bioequivalence study," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI. "We expect to initiate the pivotal bioequivalence trial in December of this year with results expected during the first quarter of 2012. If the results from this pivotal study are positive, we could be in a position to submit a New Drug Application (NDA) for BEMA Buprenorphine/Naloxone in the second half of 2012."


When I first saw the picture, I got all excited thinking it was a Suboxone patch. But I'll probably have to wait for that one.


Top
 Profile  
 
 Post subject:
PostPosted: Thu Dec 01, 2011 10:50 pm 
Offline
6 Months or More
6 Months or More
User avatar

Joined: Tue Sep 20, 2011 9:31 pm
Posts: 182
TEAR, This is very exciting it will be great to have options. How nice is that gonna be.

Thanks for this infromation
Mel :wink:

_________________
Dreams are only Dreams unless you persue them


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

All times are UTC - 5 hours [ DST ]


Who is online

Users browsing this forum: No registered users and 1 guest


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
Our Sponsors
Suboxone Forum latest topics RSS feed Subscribe to the entire forum
 

 

 
Fond Du Lac Psychiatry
Dr. Jeffrey Junig, M.D., Ph.D.

  • Board Certified Psychiatrist
  • Asst Clinical Professor, Medical College of Wisconsin

Powered by phpBB® Forum Software © phpBB Group